News from Argos Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 07, 2014, 06:00 ET Argos Therapeutics Prices Initial Public Offering

 Argos Therapeutics, Inc. today announced the pricing of its initial public offering of 5,625,000 shares of common stock at a public offering...


Feb 04, 2012, 17:30 ET Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)

 Argos Therapeutics Inc. today announced that updated results from an open label Phase 2 study of  its Arcelis™ immunotherapy,...


Oct 04, 2011, 10:44 ET Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System

Argos Therapeutics, Inc. today announced that its late scientific co-founder and scientific advisor Ralph M. Steinman, M.D., was awarded the Nobel...


Jul 29, 2011, 12:21 ET Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering

Argos Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission...


Jun 05, 2011, 11:00 ET Argos Therapeutics Presents New Phase 2 Data Showing its Arcelis™ Immunotherapy AGS-003 in Combination with sunitinib Improves Progression-Free Survival (PFS) in Patients with Advanced Renal Cell Carcinoma (RCC)

Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis™ immunotherapy for the treatment of renal...


Jun 01, 2011, 08:00 ET Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes

Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination...


May 04, 2011, 08:00 ET Argos Therapeutics' Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation

Argos Therapeutics today announced that its immunotherapy platform based on recombinant human soluble CD83 demonstrated significant promise for...


Apr 05, 2011, 08:00 ET Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Needham & Company 10th Annual Healthcare Conference and Leerink Swann Cancer Roundtable Conference

Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview and the...


Jan 31, 2011, 08:00 ET Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial

Argos Therapeutics announced today that interleukin (IL)-12 secretion can predict the potency of the company's Arcelis™ dendritic cell (DC)...


Dec 09, 2010, 08:00 ET Argos Therapeutics' Arcelis™ HIV Immunotherapy Shows Feasibility to Generate Fully Functional Dendritic Cells From Viremic Patients

Argos Therapeutics announced today that its Arcelis HIV immunotherapy, AGS-004, showed feasibility in in vitro models to generate fully functional...


Dec 07, 2010, 08:00 ET Argos Therapeutics Initiates Dosing of Patients in Phase 1 Clinical Trial of Monoclonal Antibody-Based Therapy for Treatment of Systemic Lupus Erythematosus

Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 1 clinical trial of its monoclonal antibody-based therapy,...


Nov 30, 2010, 08:00 ET Argos Therapeutics Initiates Dosing of Patients in Phase 2b Clinical Trial of Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients

Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 2b clinical trial of its Arcelis™ personalized...


Nov 11, 2010, 08:00 ET Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference

Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview and the...


Nov 09, 2010, 12:34 ET Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition

Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present on the potential of Argos'...


Nov 02, 2010, 08:00 ET Argos Therapeutics to Present About the Implementation, Cost Effectiveness and Benefits of Automation for its Arcelis™ Immunotherapy at The Cell Therapy Industry Summit-2010

Argos Therapeutics today announced that Fred Miesowicz, the company's chief operating officer and vice president of manufacturing, will present on...


Nov 01, 2010, 08:00 ET Leading Renal Cell Carcinoma (RCC) Researchers to Discuss Novel Therapies, Promise of Personalized Immunotherapy in Webinar Hosted by Argos Therapeutics

Argos Therapeutics today announced that it will host a Webinar with leading researchers in renal cell carcinoma (RCC) to discuss novel therapies,...


Oct 28, 2010, 08:00 ET Argos Therapeutics to Present a Corporate Overview, Prospects of its Arcelis™ Immunotherapy and Clinical Developments at 2010 Mid-Atlantic Bio

Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview,...


Oct 26, 2010, 08:00 ET Leading Renal Cell Carcinoma (RCC) Researchers to Discuss Novel Therapies, Promise of Personalized Immunotherapy in Webinar Hosted by Argos Therapeutics

Argos Therapeutics today announced that it will host a Webinar with leading researchers in renal cell carcinoma (RCC) to discuss novel therapies,...


Oct 18, 2010, 08:12 ET Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference

Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present an overview of its...


Oct 08, 2010, 08:00 ET Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe

Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present recent clinical developments...